Evaluation of HCPTd1, d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 33, 2005, Pages 5221-5225

  Yu, Zhi Jian ^a   Yu, Jia Wei ^a   Cai, Wei ^a   Yuan, Hong Xin ^a   Li, Xiao Yan ^a   Yuan, Ye ^a   Chen, Jian Ping ^a   Wu, Xiao Yin ^a   Yao, Deng Fu ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Hydroxycamptothecin; Portal venous embolization; Transcatheter arterial embolization

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ALPHA FETOPROTEIN; DOXORUBICIN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE;

ABDOMINAL BLEEDING; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; EVALUATION; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMOTHORAX; PORTAL VEIN; PROTEIN BLOOD LEVEL; STANDARDIZATION; TUMOR VOLUME; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HEPATIC ARTERY; LIVER TUMOR; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; TREATMENT OUTCOME;

EID: 26244431724     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the world-wide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346
3. Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringes B, Meyers WC. Hepatocellualr carcinoma. Br J Surg 1998; 85: 1319-1331
4. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
5. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390-395
6. Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, Meng XY. Abnormal expression of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-769
7. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-1726
8. Zhang R, Li Y, Cai Q, Liu T, Sun H, Chambless B. Preclinical Pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother Pharmacol 1998; 41: 257-267
9. Zhou YH, Xu B. Advanced on CPT drugs in combined applications of anticancer. Tumor 1998; 18: 302-304
10. Yu ZJ, Zheng YQ, Huang JF. Servey of treatment with transcatheter arterial embolization of late-stage hepatic carcinoma. Nantong Yixueyuan Xuebao 1991; 11: 102-104
11. Yu ZJ, Meng XY, Xu KC, Ge ZJ. Hydroxycamptothecine and cantharidin combined with crsplatin and lipiodol through transcatheter arterial emobolization in hepatocellular carcinoma. Zhongguo Zhongxiyi Zazhi 1995; 1: 175-178
12. Yu ZJ, Meng XY, Cheng JP, Liu YH, Zhou YQ, Huang JF, Wu JX, Wu XY. Clinical observations on the sequencial TACE, TSAi, and PVE treatment in advanced hepatocellular carcinoma with portal vein tumor thrombius. Zhonghua Xiaohua Zazhi 1996; 16: 32-35
13. Yu ZJ, Meng XY. Servey of treatment of hepatic carcinoma with HCPT, CDDP, 5-FU through transcatheter arterial embolization. Zhongguo Linchuang Zhongliu Zazhi 1998; 25: 73-75
14. Guan ZZ. Clinical study of 10-hydroxy-camptothecin in China: standardized reevaluation on necessary. Aizheng 2001; 20: 1333-1334
15. The liver cancer committee of Chinese anticancer association. Diagnostic criteria of primary hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi 2000; 8: 135
16. El-Saadani MA. A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. J Exp Ther Oncol 2004; 4: 19-24
17. Zhang L, Li S, Liao H, Jiang WQ, Guqn ZZ. Phase 1 trial of pharmaco-kinetics and human tolerability to 10-hydroxycamptothecin in patients with advanced malignancy. Aizheng 2001; 20: 1391-1395
18. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangio-carcinoma, and gallbladder carcinoma. Cancer 2004; 101: 578-586
19. Pourgholami MH, Morris DL. 1,25-Dihydroxyvitamin D(3) in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J Steroid Biochem Mol Biol 2004; 89-90: 513-518
20. Heinemann LA, Thomas DB, Mohner M. MILTS Collaborative Study Team. Multicentre international liver tumour study protocol of the case-control study on hepatocellular cancer. Pharmacoepidemiol Drug Saf 1996; 5: 173-186
21. Date M, Fukuchi K, Namiki Y, Okumura A, Morita S, Takahashi H, Ohura K. Therapeutic effect of photodynamic therapy using PAD-S31 and diode laser on human liver cancer cells. Liver Int 2004; 24: 142-148
22. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization. for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000; 73: 109-114
23. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54
24. Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma. Ann Surg 2004; 240: 299-305
25. Goshima S, Kanematsu M, Matsuo M, Kondo H, Kato H, Yokoyama R, Hoshi H, Moriyama N. Nodule-in-nodule appearance of hepatocellular carcinomas: Comparison of gadolinium-enhanced and ferumoxides-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 250-255
26. Acunas B, Rozanes I. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol 1999; 32: 86-89
27. Huang HQ, Jiang WQ, Hu XH, Lin XB, Liu KF, Li YH, Lin Z, Shen WX, Chen Q, He YJ, Guan ZZ. Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies. Aizheng 2003; 22: 1334-1338
28. Zhou JJ, Liu J, Xu B. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol Sin 2001; 22: 827-830
29. Platzer P, Thalhammer T, Reznicek G, Hamilton G, Zhang R, Jager W. Metabolism and biliary excretion of the novel anti-cancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. Int J Oncol 2001; 19: 1287-1293
30. Zhang XW, Qing C, Xu B. Apoptosis induction and cell cycle perturbation in human hepatoma hep G2 cells by 10-hydroxycamptothecin. Anticancer Drugs 1999; 10: 569-576
31. Zhang XW, Jiang JF, Xu B. Differentiation-inducing action of 10-hydroxy-camptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin 2000; 21: 364-368
32. Zangos S, Gille T, Eichler K, Engelmann K, Woitaschek D, Balzer JO, Mack MG, Thalhammer A, Vogl TJ. Transarterial chemoembolization in hepato- cellular carcinomas: technique, indications, and results. Radiologe 2001; 41: 906-914
33. Livraghi T. Treatment of hepatocellular carcinoma by interventional methods. Eur Radiol 2001; 11: 2207-2219
34. Loewe C, Cejna M, Schoder M, Thurnher MM, Lammer J, Thurnher SA. Arterial embolization of unresectable hepatocellular carcinoma with use of cyanoacrylate and lipiodol. J Vasc Interv Radiol 2002; 13: 61-69